观点：欧洲克罗恩病和结肠炎组织成员对生物类似单克隆抗体的认识与观点
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
作者信息
Danese Silvio, Fiorino Gionata, Michetti Pierre
机构信息
IBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
IBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
出版信息
J Crohns Colitis. 2014 Nov;8(11):1548-50. doi: 10.1016/j.crohns.2014.06.007. Epub 2014 Jul 6.
BACKGROUND
Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies.
METHODS
A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
背景
最近，两种英夫利昔单抗生物类似单克隆抗体（mAb）已获欧洲药品管理局批准，用于包括炎症性肠病（IBD）在内的所有免疫介导的炎症性疾病（IMID）。目前胃肠病学家，尤其是IBD专家对生物类似药的了解尚不清楚。因此，我们开展了一项网络调查，以评估IBD专家对生物类似mAb的认知度及其使用这些疗法的意愿。
方法
在欧洲克罗恩病和结肠炎组织（ECCO）的后勤支持下，开展了一项包含15个问题的匿名多项选择网络调查，问题涵盖生物类似药最相关的方面。通过电子邮件邀请随机挑选的ECCO成员参与。对回复进行描述性分析。
Zotero 插件